Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2 Trials of TH-4000, a Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor

Marketwired
Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2 Trials of TH-4000, a Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor
Threshold Pharmaceuticals Logo
View Comments (0)